Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc. demonstrates a positive outlook due to the potential for early intervention in neurodegenerative diseases, as indicated by its amended protocol for PBFT02, which aims to maximize treatment benefits by aligning closer to registrational trial standards. The company has reported encouraging data from its June 2025 interim upliFT-D trial, showcasing a sustained mean increase in CSF PGRN levels, suggesting effective therapeutic impact over 18 months. Additionally, the prospect of accelerated regulatory approval based on biomarker endpoints could shorten trial timelines and enhance Passage Bio's market positioning, especially if its performance aligns favorably with competitors in similar stages of development.

Bears say

Passage Bio Inc. operates in a high-risk sector, focusing on gene therapy for rare CNS disorders, and is currently facing significant challenges that contribute to a negative financial outlook. Key concerns include potential delays in clinical timelines for its pipeline products, PBGM01 and PBFT02, which could be exacerbated by unforeseen safety signals and regulatory hurdles, ultimately affecting market sentiment and revenue forecasts. Additionally, the company may encounter constraints related to manufacturing capacity, which could further hinder its ability to deliver on growth expectations in the competitive gene therapy landscape.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.